{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '9.4.1.', 'Physical Examinations', 'A complete physical examination will include, at a minimum, assessments of the', 'Skin, Cardiovascular, Respiratory, Gastrointestinal and Neurological systems.', 'Height, weight will also be measured and recorded.', 'Investigators should pay special attention to clinical signs related to previous', 'serious illnesses.', '9.4.2.', 'Vital Signs', 'Vital signs will be performed at the time points specified in the SoA table', '(Section 2) prior to conducting spirometry and prior to taking study treatment.', 'Blood pressure (systolic and diastolic) and pulse measurements will be assessed', 'in the sitting position after approximately 5 minutes rest.', 'A single set of values will be collected and recorded in the source', 'documentation and eCRF.', '9.4.3.', 'Electrocardiograms', 'A single 12-lead ECG and rhythm strip will be recorded after measurement of', 'vital signs and prior to spirometry. Recordings will be made at the time-points', 'defined in the SoA table (Section 2). All ECG measurements will be made with', 'the participant in a supine position having rested in this position for', 'approximately 5 minutes before each reading.', 'For participants who meet the QTc, protocol defined stopping criteria, triplicate', 'ECGs (over a brief period of time) should be performed (Section 8.1.1).', 'The Investigator, a designated sub-Investigator or other appropriately trained', 'site personnel will be responsible for performing each 12-lead ECG. The', 'Investigator must provide his/her dated signature on the original paper tracing,', 'attesting to the authenticity of the ECG machine interpretation.', '9.4.4.', 'Clinical Safety Laboratory Assessments', 'Refer to Appendix 8 for the list of clinical laboratory tests to be performed and', 'to the SoA for the timing and frequency.', 'The Investigator must review the laboratory report, document this review, and', 'record any clinically relevant changes occurring during the study in the AE', 'section of the eCRF. The laboratory reports must be filed with the source', 'documents. Clinically significant abnormal laboratory findings are those which', 'are not associated with the underlying disease, unless judged by the Investigator', \"to be more severe than expected for the participant's condition.\", 'All laboratory tests with values considered clinically significantly abnormal', 'during participation in the study or within 5 days after the last dose of study', 'treatment should be repeated until the values return to normal or baseline or are', '69']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'no longer considered significantly abnormal by the Investigator or medical', 'monitor.', 'If such values do not return to normal/baseline within a period of time judged', 'reasonable by the Investigator, the etiology should be identified and the sponsor', 'notified.', 'All protocol-required laboratory assessments, as defined in Appendix 8, must be', 'conducted in accordance with the laboratory manual and the SoA.', '9.5.', 'Pharmacokinetics', 'Pharmacokinetic parameters are not evaluated in this study.', '9.6.', 'Pharmacodynamics', 'Pharmacodynamic parameters are not evaluated in this study.', '9.7.', 'Genetics', 'Information regarding genetic/ pharmacogenetic (PGx) research is included in', 'Appendix 9. The IEC/IRB and, where required, the applicable regulatory agency must', 'approve the PGx and genetic assessments before these can be conducted. The', 'approval(s) must be in writing and will clearly specify approval of the PGx and genetic', 'assessments (i.e., approval of Appendix 9).', 'In some cases, approval of the PGx and genetic assessments can occur after approval is', 'obtained for the rest of the study. If so, then the written approval will clearly indicate', 'approval of the PGx and genetic assessments is being deferred and the study, except for', 'PGx and genetic assessments, can be initiated. When PGx and genetic assessments will', 'not be approved, then the approval for the rest of the study will clearly indicate this and', 'therefore, PGx and genetic assessments will not be conducted.', '9.8.', 'Biomarkers', 'Biomarkers are not evaluated in this study.', '9.9.', 'Medical Resource Utilization and Health Economics', 'Medical Resource Utilization and Health Economics parameters are not evaluated in this', 'study.', '9.10.', 'Smoking Cessation Counselling', 'During Visits 1 and 4, or Study Discontinuation, participants will be given smoking', 'cessation counselling. This will include advice regarding the following:', 'the health effects that smoking may cause', 'the health benefits that may result with smoking cessation', '70']\n\n###\n\n", "completion": "END"}